DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
IQVIA Holdings Inc. (NYSE: IQV), a company dedicated to using analytics
and science to help healthcare stakeholders find better solutions for
patients, is announcing a novel alliance with the FDA Center for
Biologics Evaluation and Research (CBER) to combine advanced analytics
and unparalleled information assets to monitor and assist in the
evaluation of safety and effectiveness of various CBER-regulated
vaccines, blood products and other biologics.
As part of this important public health collaboration, IQVIA has teamed
up with the Observational Health Data Science and Informatics (OHDSI)
initiative and its world-class team of healthcare experts and unique
data assets from Columbia University, Stanford University, Georgia
Institute of Technology, University of California, Los Angeles (UCLA)
and the Regenstrief Institute at the Indiana University School of
Medicine to enhance the function and outputs of the initiative.
This agreement launches CBER’s Biologics Effectiveness and Safety (BEST)
Initiative as a new component of the ongoing Sentinel Initiative to
develop new capacity and capabilities within the following areas:
-
Boosting blood safety surveillance in support of FDA efforts to
further develop a national hemovigilance program;
-
Evaluating post-market safety and effectiveness for biologic products
using innovative approaches such as query tools, machine learning,
artificial intelligence and natural language processing; and
-
Assessing health outcomes and evaluating biologic products use.
We believe biologics surveillance will benefit from IQVIA’s
near-real-time data and analytics specific to CBER-regulated vaccines,
blood and blood products, tissues and other biologics.
IQVIA brings its IQVIA CORE™ to the agreement, leveraging one of the
world’s largest curated healthcare information sources, advanced
analytics, leading technologies and extensive industry knowledge across
diseases, geographies and scientific methods.
“We’re thrilled to be part of this important program to protect public
health by fully tapping into data that we generate every day,” said Jon
Resnick, president, Real-World & Analytics Solutions, IQVIA. “Putting
powerful healthcare analytic capabilities and deep expertise together
will help us all benefit from safer medicines and better health
outcomes.”
About IQVIA
IQVIA (NYSE: IQV) is a leading global provider of information,
innovative technology solutions and contract research services focused
on using data and science to help healthcare clients find better
solutions for their patients. Formed through the merger of IMS Health
and Quintiles, IQVIA offers a broad range of solutions that harness
advances in healthcare information, technology, analytics and human
ingenuity to drive healthcare forward. IQVIA enables companies to
rethink approaches to clinical development and commercialization,
innovate with confidence as well as accelerate meaningful healthcare
outcomes. IQVIA has approximately 55,000 employees in more than 100
countries, all committed to making the potential of human data science a
reality. IQVIA’s approach to human data science is powered by the IQVIA
CORE™, driving unique actionable insights at the intersection of big
data, transformative technology and analytics with extensive domain
expertise.
IQVIA is a global leader in protecting individual patient privacy. The
company uses a wide variety of privacy-enhancing technologies and
safeguards to protect individual privacy while generating and analyzing
the information that helps their customers drive human health outcomes
forward. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap into a
deeper understanding of diseases, human behaviors and scientific
advances, in an effort to advance their path toward cures. To learn
more, visit www.IQVIA.com.
IQVIAFIN
Click
here to subscribe to Mobile Alerts for IQVIA.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180206006411/en/
Source: IQVIA Holdings Inc.